[Clinical trial of parenteral trimethoprim-sulfamethoxazole].
The combination of trimethoprim-sulfamethoxazole has been used successfully in various infections. However the use of the combination was limited, due to the lack of a parenteral form of the drug. In this study a parenteral (i.m.) form of trimethoprim-sulfamethoxazole was given to 35 patients with various infections due to susceptible bacteria to the drug. Twenty-four patients had urinary tract infections, and 7 had various infections with gram negative organisms, and 4 had staphylococcal infections. In patients with urinary tract infection the cure rate was 62.5%. Twenty five per cent of the patients had persistent infection after treatment, and 12,5% had superinfection. The overall cure rate was 71,4% in 35 patients. No side effect was observed.
D000284:Administration, Oral; D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D006801:Humans; D013420:Sulfamethoxazole / Q000008:administration & dosage*; D014295:Trimethoprim / Q000008:administration & dosage*
D004338:Drug Combinations; D014295:Trimethoprim; D013420:Sulfamethoxazole
Parenteral trimethoprim--sulfamethoxazole'un klinik etkinliği.